V920 clinical trials
How each study uses V920 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BPSC-1001
- 1
Studies by the year they started
3 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
Who runs them
Industry 2 · Other 1
Merck Sharp & Dohme LLC (2) · Canadian Immunization Research Network (1)
Studies
Open first, then newest update. How each study uses V920 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-EbolaCompletedPhase 2Canadian Immunization Research NetworkNCT03031912Written as V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine
- Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)CompletedPhase 1Merck Sharp & Dohme LLCNCT02314923Written as V920 Vaccine
- Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)CompletedPhase 3Merck Sharp & Dohme LLCNCT02503202Written as V920 Consistency Lot A